Abdul Rafeh Naqash, a medical oncologist and phase I clinical trialist at the University of Oklahoma Health Stephenson Cancer Center, was granted an Impact Award from SWOG Cancer Research Network’s Hope Foundation for Cancer Research.
A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
